Ligustrazine attenuates myocardial ischemia reperfusion injury in rats by activating the phosphatidylinositol 3-kinase/Akt pathway.

摘要

To the Editor: Coronary revascularization has been well-established as the most effective treatment of limiting the eventual infarct size for coronary artery diseases. However, reperfusion can elicit a number of adverse reactions that may limit its beneficial actions. Although reduction of ischemia reperfusion (IR) injury through the use of antioxidant therapy, calcium-channel blockers, sodium-hydrogen exchange inhibitors, and antiinflammatory drugs has previously been attempted in many studies, few agents are clinically available for protecting the heart from IR injury [1].